Myeloma UK   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Edinburgh United Kingdom (1998)

Organization Overview

First Clinical Trial
2013
NCT02145715
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Myeloma UK